These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 12720142

  • 1. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C, Miqueleiz S, Bernuzzi P, Tresoldi E, Rossi V, D'avanzo G, Filippini D, Morra E.
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M.
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [Abstract] [Full Text] [Related]

  • 4. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
    Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P.
    J Clin Oncol; 2005 Jul 20; 23(21):4662-8. PubMed ID: 16034042
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
    Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Miqueleiz S, Bernuzzi P, Nosari AM, Lazzarino M.
    Leukemia; 2004 Sep 20; 18(9):1512-7. PubMed ID: 15322559
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2007 Apr 20; 25(12):1570-5. PubMed ID: 17353550
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.
    Stalnikiewicz L, Carrotte-Lefebvre I, Detourmignies L, Rose C, Cazin B, Leblond V, Morel P.
    Semin Oncol; 2003 Apr 20; 30(2):216-9. PubMed ID: 12720139
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
    Björkholm M, Johansson E, Papamichael D, Celsing F, Matthews J, Lister TA, Rohatiner AZ.
    Semin Oncol; 2003 Apr 20; 30(2):226-30. PubMed ID: 12720141
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA.
    Biol Blood Marrow Transplant; 2006 Aug 20; 12(8):845-54. PubMed ID: 16864055
    [Abstract] [Full Text] [Related]

  • 17. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
    Jondeau K, Alterescu R, Franc B, Davi F, Massé JM, Boukour S, Le Parc JM, Cramer EM.
    Eur J Haematol; 2006 Jul 20; 77(1):74-9. PubMed ID: 16827885
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA.
    Semin Oncol; 2003 Apr 20; 30(2):110-5. PubMed ID: 12720118
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.